Rasmus Lofmark-Jansson

BioPharmaceuticals R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data.

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data.

Journal: Clinical pharmacology and therapeutics

Published: February 11, 2026

Systemic Pharmacokinetic Principles of Therapeutic Peptides.

Systemic Pharmacokinetic Principles of Therapeutic Peptides.

Journal: Clinical pharmacokinetics

Published: August 21, 2025

Virtual Twin-PBPK Modelling: A Step Toward Precision Dosing in Patients with Obesity.

Virtual Twin-PBPK Modelling: A Step Toward Precision Dosing in Patients with Obesity.

Journal: The AAPS journal

Published: July 22, 2025

Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African Trypanosomiasis.

Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African Trypanosomiasis.

Journal: The AAPS journal

Published: May 05, 2025

Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio.

Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio.

Journal: Drug discovery today

Published: January 22, 2025

Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists.

Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists.

Journal: Pharmaceutics

Published: August 19, 2024

SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling.

SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling.

Journal: Cardiovascular diabetology

Published: July 30, 2024

Gastric Bypass vs Diet and Cardiovascular Risk Factors: A Nonrandomized Controlled Trial.

Gastric Bypass vs Diet and Cardiovascular Risk Factors: A Nonrandomized Controlled Trial.

Journal: JAMA surgery

Published: July 03, 2024

Oral Drug Dosing After Gastric Bypass and Diet-Induced Weight Loss: Simpler Than We Think? Lessons Learned From the COCKTAIL Study.

Oral Drug Dosing After Gastric Bypass and Diet-Induced Weight Loss: Simpler Than We Think? Lessons Learned From the COCKTAIL Study.

Journal: Clinical pharmacology and therapeutics

Published: January 31, 2024

Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals.

Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals.

Journal: Clinical pharmacokinetics

Published: October 08, 2023

Normoglycemia and physiological cortisone level maintain glucose homeostasis in a pancreas-liver microphysiological system.

Normoglycemia and physiological cortisone level maintain glucose homeostasis in a pancreas-liver microphysiological system.

Journal: Communications biology

Published: June 18, 2023

Proteome deconvolution of liver biopsies reveals hepatic cell composition as an important marker of fibrosis.

Proteome deconvolution of liver biopsies reveals hepatic cell composition as an important marker of fibrosis.

Journal: Computational and structural biotechnology journal

Published: April 04, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026